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nursing homes. As this study was not representative, it cannot be
used to draw reliable conclusions. Therefore, the aim of the
current study was to quantify the number of drug administration
errors in German nursing homes. The focus was on checking the
administration of regularly scheduled solid oral medication.
METHODS: The prospective study was carried out in three
nursing homes during a period of eight weeks. The drug admin-
istration errors were divided into seven categories: wrong time
of administration, wrong dosage, wrong drug, missing drug,
surplus drug, incorrect pill division and damaged drug.
RESULTS: The study included 196 residents. In total, 8798 daily
doses were screened. This equals a total number of 48,512
inspected single medications. On average, every nursing home
resident received 5.4 solid oral drugs per day. In 53% of the
nursing home residents one or more drug administration errors
were detected. Based on the 8798 screened daily doses the error
rate was 7.3%. The majority of all drug supply errors (50%)
occurred in the category incorrect pill division. This is followed
by the category missing drug with 22%, surplus drug with 10%,
wrong time of administration with 8%, damaged drug with 6%,
wrong dosage with 4% and wrong drug with 0%. CONCLU-
SION: The ﬁndings of the study show that there is still a need for
action with regard to drug administration in German nursing
homes.
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OBJECTIVE: The opponents of the socialization of health care
hypothesize that socialization of health care could lead to
decrease quality of care. The aim of our study was to compare
the quality of care delivered to a privately insured population
compared to those covered by government subsidized Medicaid
plan in the same region. METHODS: Administrative claims
data from July 2004 through June 2005 were used from a
private health plan and the Medicaid plan within the same state
in the Southeastern US. Two quality indicators from the Health
Plan Employer Data and Information Set (HEDIS) were adapted
and used to compare compliance rates between the privately
insured and Medicaid populations (Table 1). Based on the speci-
ﬁcations of each indicator, children who met relevant criteria
were identiﬁed as the denominator. Of those, children that
received the indicated intervention were identiﬁed as the
numerator. Population-level rates were calculated for each
quality indicator for both plans. RESULTS: Children in the
private health plan received the indicated quality care much
more frequently than the Medicaid population, with nearly
3-fold differences in compliance rates. Varicella zoster virus
(VZV) vaccines and measles, mumps and rubella (MMR) vac-
cines were included in the analysis for 2 year old children. The
private plan had a denominator of 4222 children and the Med-
icaid plan had 15,653 children for both measures. Eighty-two
percent of private plan children received a VZV vaccine com-
pared to 29% of Medicaid children. Eighty-four percent of
private plan children received an MMR vaccine compared to
29% of Medicaid children. CONCLUSION: Children covered
by Medicaid plans are signiﬁcantly less likely to receive quality
health care than compared to those who have private insurance
coverage. Further studies are needed to investigate to what
degree this wide disparity is driven by socioeconomic factors
and the socialization of health care.
MUSCULAR-SKELETAL DISORDERS—
Clinical Outcomes Studies
PMS1
EFFECT OF BISPHOSPHONATES ON FRACTURES IN
POSTMEOPAUSALWOMEN:A SYSTEMATIC LITERATURE
REVIEW
Reddy P1, Fiumara K2,YehYC1, Clapp M3, ChurchillW2, Blackwell AD4
1Partners Healthcare, Charlestown, MA, USA, 2Brigham and Women’s
Hospital, Boston, MA, USA, 3Massachusetts General Hospital, Boston,
MA, USA, 4Global Health Outcomes, Smayrna, GA, USA
OBJECTIVE: While bisphosphonates have been available for
many years, new drugs in this class have recently become avail-
able. We sought to understand whether differences exist on
fracture risk and adverse events among oral (i.e., alendronate,
risedronate, ibandronate) and intravenous (i.e., ibandronate,
pamidronate, and zoledronic acid) bisphosphonates available in
the United States in postmenopausal women. METHODS: A
search of the English-language literature in Medline and
Cochrane databases was conducted from 1997 to 2007 using
combinations of these search terms: bisphosphonates, alendr-
onate, risedronate, zoledronic acid, pamidronate, ibandronate,
fracture, adverse events, and osteoporosis. Articles were included
if they were meta-analyses or randomized controlled trials (RCT)
and provided information on fracture risk and adverse events.
RESULTS: In the most recent meta-analysis, alendronate
(n = 12,099 patients; 11 trials) and risedronate (n = 13,795
patients; 6 trials) reduced the risk of vertebral fractures
(RR:0.55, 95%CI 0.45–0.67; RR:0.61, 95%CI 0.50–0.76) and
non-vertebral fractures (RR:0.84, 95%CI 0.74–0.94; RR:0.80,
95%CI 0.72–0.90), including hip fractures (RR:0.61, 95%CI
0.40–0.92; RR:0.74, 95%CI 0.59–0.94). Similarly, in a RCT
among 7765 women, the incidence of vertebral fractures, non-
vertebral, and hip fractures was signiﬁcantly reduced with
zoledronic acid (RR:0.30, 95%CI 0.24–0.38; RR:0.75, 95%CI
0.64–0.87; RR:0.59, 95%CI 0.42–0.83). In contrast, oral iban-
dronate (n = 1952) lowered the risk of vertebral fractures
(RR:0.62, 95%CI 0.41–0.75) but not nonvertebral fractures.
Data on fracture risk with pamidronate were not identiﬁed.
Adverse events were similar between bisphosphonates and
placebo in all included studies, except with zoledronic acid where
serious atrial ﬁbrillation (1.3% vs. 0.5%; p < 0.001), an increase
in Scr >0.5 mg/dL (1.2% vs. 0.4%; p = 0.001), and urinary
protein >2+ (0.5% vs. 0.2%; p = 0.06) were higher with treat-
ment compared to placebo. CONCLUSION: This evidenced-
based literature review shows that clinical differences among
bisphosphonates exist. This suggests that selection of bisphos-
phonates needs to be individualized to maximize the desired
effect and minimize risks.
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OBJECTIVE: Three biological agents (adalimumab, etanercept
and inﬂiximab) are registered for psoriatic arthritis (PsA) by the
EMEA or the FDA. Our objectives were to compare the efﬁcacy
of the available biologicals in PsA and to compare their effect
sizes by standardized improvement criteria of signs and symp-
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toms. METHODS: Randomized controlled trials (RCT) of adali-
mumab, etanercept and inﬂiximab involving patients with
PsA were searched in MEDLINE by Cochrane Highly Sensitive
Search Strategy. The quality of selected studies was measured
using the Jadad-score. Two clinical outcomes were analyzed:
the rate of patients achieving at least 20% improvement by the
American College of Rheumatology criteria (ACR20) and the
Psoriatic Arthritis Response Criteria (PsARC). Review Manager
4.2 software was applied for the analysis, using the number
needed to treat (NNT) and relative risk (RR) as statistical
variables. Due to lack of face-to-face evidence on biologicals, in-
direct comparison was conducted applying Butcher’s method.
RESULTS: Six RCTs were identiﬁed involving altogether 982
patients on the active treatment arms: adalimumab (n = 413),
etanercept (n = 265) and inﬂiximab (n = 304). All trials were
placebo controlled, the primary follow-up time was 12–16 weeks
and the primary outcome was ACR20. The NNTs (95% conﬁ-
dence intervals) for adalimumab, etanercept and inﬂiximab were
2.6 (2.1–3.2), 2.1 (1.7–2.7) and 2.0 (1.7–2.4) patients to achieve
ACR20 outcome and 2.9 (2.3–4.0), 2.2 (1.8–2.8) and 2.0
(1.6–2.4) to fulﬁll PsARC outcome, respectively. Indirect pair-
wise comparisons of TNF-alpha inhibitors yielded the RR of
0.87 (0.50–1.51) for adalimumab vs. etanercept, of 1.37 (0.72–
2.61) for inﬂiximab vs. etanercept and of 1.57 (0.87–2.86) for
inﬂiximab vs. adalimumab. CONCLUSION: Adalimumab, etan-
ercept and inﬂiximab are effective for the treatment of PsA. Both
the NNTs and the responsiveness of the three drugs at PsARC
and ACR20 outcomes are similar. Indirect comparison did not
reveal signiﬁcant difference in the efﬁcacy among the TNF-alpha
inhibitors in PsA.
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OBJECTIVE: To compare the efﬁcacy of etoricoxib, lumira-
coxib, celecoxib, non-selective (ns) NSAIDs and acetaminophen
in the treatment of osteoarthritis. METHODS: RCTs investigat-
ing the effects of acetaminophen 4000 mg, diclofenac 150 mg,
naproxen 1000 mg, ibuprofen 2400 mg, celecoxib 100–400 mg,
lumiracoxib 100–400 mg, and etoricoxib 60 mg with a treat-
ment duration of at least two weeks were identiﬁed with a
systematic literature search. Endpoints of interest were pain,
physical function and patient global assessment of disease status
(PGADS). Pain and physical function reported on VAS or
LIKERT scales were translated into effect sizes (ES). PGADS was
reported on a 0–100 mm VAS scale. An ES 0.2–0.5 was deﬁned
as a “small” treatment effect, whereas ES of 0.5–0.8 and >0.8were
deﬁned as “moderate” and “large”, respectively. Outcomes of all
trials were analyzed simultaneously with a Bayesian mixed treat-
ment comparison. A negative estimate indicates favourable out-
comes. RESULTS: There is an 84% probability that etoricoxib
60 mg shows the greatest improvement in pain of all interventions
compared, followed by diclofenac 150 mg (7% probability) and
ibuprofen 2400 mg (4%). Etoricoxib 60 mg showed an ES of
-0.62 (95%Credible Interval -0.78; -0.45) relative to placebo, an
ES of -0.12 (-0.33; 0.07) relative to diclofenac 150 mg, and an ES
of -0.21 (-0.50; 0.07) relative to ibuprofen. Regarding physical
functioning, there is an 85% probability that etoricoxib 60 mg
showed the greatest improvement, followed by diclofenac 150 mg
(8% probability) and ibuprofen 2400 mg (4%). ESs of etoricoxib
60 mg relative to diclofenac 150 mg and ibuprofen 2400 mgwere
-0.12 (-0.34; 0.08), and -0.23 (-0.53; 0.06) respectively. The
greatest improvements regarding PGADS were expected with
diclofenac (29% probability) followed by etoricoxib (25%).
CONCLUSION: The current study estimated the efﬁcacy of
acetaminophen, nsNSAIDs, and COX-2 selective NSAIDs in OA
and demonstrated that etoricoxib 60 mg is likely to result in the
greatest improvements in pain and physical function.
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OBJECTIVE: The aim of our study was to examine the relation-
ship between volume (annual number of patients) and outcome
(30 days mortality) in patients with femoral neck fracture.
METHODS: Data derived from the nationwide dataset of the
National Health Insurance Fund Administration. Patients aged
over 60 years with femoral neck fracture admitted to acute care
hospital were included into the study. 30 days mortality follow-
ing the primary surgical treatment was analyzed. We examined
the relationship between volume (annual number of patients) and
outcome (30 days mortality). First quintiles with similar patient
number was applied (method I), than the patient number itself
was the variable (method II). Several other covariates were
included into the analysis: sex, age, co-morbidities, type and
location of fracture, type of surgery (ostheosynthesis, arthro-
plasty), within 30 days complications, hospital type, day of
surgery and surgical delay. The association between covariates
was evaluated with logistic regression analysis (OR: odds ratio,
95% CI: conﬁdence interval, p value). RESULTS: Altogether
3783 patient from 65 different hospitals were included into the
study. The average 30 days mortality was 8.99 %, ranging
between 7.82–10.0 % (method I). Using the volume data itself as
continuous variable (method II), the connection between volume
and outcome could not be proven (ORunivariate = 0.998,
CI: 0.9974–1.0005, p: 0.1779; ORmultivariate = 0.9987, CI:
0.9962–1.0013, p: 0.3378). We did not ﬁnd any relationship
between hospital volume and outcome in patients with femoral
neck fracture. However it is important to highlight the role of
hospital type, where treatment at medical university (medical
school) is associated with signiﬁcantly lower 30 days mortality.
CONCLUSION: We would like to emphasize on the analysis of
our nationwide dataset that initial treatment in high-volume
hospitals was not associated with lower 30 days mortality.
However, type of hospital (teaching status) seems to be more
important predictor of 30 days mortality.
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OBJECTIVE: To understand the impact of the October 2004
withdrawal of rofecoxib on prescription analgesic use for arthri-
tis patients who had been taking this medication. METHODS:
Patients were selected from the MarketScan databases who,
during January-September 2004, had a diagnosis of osteoarthri-
tis on a medical claim and who ﬁlled prescriptions for at least 90
days of therapy with rofecoxib, an alternative COX-2 inhibitor
(celecoxib), or a branded, non-selective, nonsteroidal, anti-
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